文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

延长时间与较短时间清醒俯卧位对COVID-19急性呼吸衰竭患者的影响:多中心随机对照试验

Prolonged vs shorter awake prone positioning for COVID-19 patients with acute respiratory failure: a multicenter, randomised controlled trial.
PubMed 文献 · Intensive Care Med · 2024-08-01
一句话结论COVID-19相关急性低氧性呼吸衰竭非插管患者延长清醒俯卧位(目标>12 h/d×7天)较标准治疗降低28天内插管率(17% vs 27%,RR 0.62),且不良反应少。

该多中心随机开放标签试验在中国12家医院纳入409例COVID-19相关急性低氧性呼吸衰竭非插管患者,随机分为延长清醒俯卧位组(205例,目标>12 h/d×7天)与标准治疗组(204例,较短时间清醒俯卧位)。随机后前7天俯卧位中位时长延长组12 h/d(IQR 12-14)vs 标准组5 h/d(IQR 2-8)。意向治疗分析显示延长组插管35例(17%)vs 标准组56例(27%),RR 0.62(95%CI 0.42-0.9),插管HR 0.56(0.37-0.86)、死亡HR 0.63(0.42-0.96)。预设不良事件发生率低且两组相似。作者结论认为延长清醒俯卧位降低插管率且无显著伤害。

要点

  • 延长清醒俯卧位组插管17%(35/205)vs 标准治疗组27%(56/204),RR 0.62(95%CI 0.42-0.9)。
  • 28天内插管HR 0.56(95%CI 0.37-0.86),死亡HR 0.63(95%CI 0.42-0.96),均支持延长俯卧位。
  • 随机后前7天俯卧位中位时长:延长组12 h/d(IQR 12-14)vs 标准组5 h/d(IQR 2-8)。
  • 预设不良事件发生率低且两组相似。
  • 作者结论支持对COVID-19相关急性低氧性呼吸衰竭患者延长清醒俯卧位。

适用人群与场景

  • 中国12家医院收治的COVID-19相关急性低氧性呼吸衰竭非插管(未气管插管)患者。

处置流程与药物剂量

  • 延长清醒俯卧位组目标为每日俯卧位>12 h、持续7天。
  • 标准治疗组采用较短时间清醒俯卧位。

研究设计与关键结果

  • 多中心随机开放标签试验,中国12家医院,409例COVID-19相关急性低氧性呼吸衰竭非插管患者,随机分为延长清醒俯卧位组(n=205)与标准治疗组(n=204)。
  • 随机后前7天俯卧位中位时长:延长组12 h/d(IQR 12-14)vs 标准组5 h/d(IQR 2-8)。
  • 意向治疗分析:28天内插管延长组35例(17%)vs 标准组56例(27%),RR 0.62(95%CI 0.42-0.9)。
  • 28天内插管HR 0.56(95%CI 0.37-0.86),死亡HR 0.63(95%CI 0.42-0.96),均为延长清醒俯卧位 vs 标准治疗。
  • 预设不良事件发生率低且两组相似。

证据类型、等级与局限

  • 研究类型:多中心随机开放标签对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,对COVID-19相关急性低氧性呼吸衰竭患者延长清醒俯卧位可降低插管率且无显著伤害,支持延长清醒俯卧位。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Awake prone positioning has been reported to reduce endotracheal intubation in patients with coronavirus disease 2019 (COVID-19)-related acute hypoxemic respiratory failure (AHRF). However, it is still unclear whether using the awake prone positioning for longer periods can further improve outcomes.

METHODS: In this randomized, open-label clinical trial conducted at 12 hospitals in China, non-intubated patients with COVID-19-related AHRF were randomly assigned to prolonged awake prone positioning (target > 12 h daily for 7 days) or standard care with a shorter period of awake prone positioning. The primary outcome was endotracheal intubation within 28 days after randomization. The key secondary outcomes included mortality and adverse events.

RESULTS: In total, 409 patients were enrolled and randomly assigned to prolonged awake prone positioning (n = 205) or standard care (n = 204). In the first 7 days after randomization, the median duration of prone positioning was 12 h/d (interquartile range [IQR] 12-14 h/d) in the prolonged awake prone positioning group vs. 5 h/d (IQR 2-8 h/d) in the standard care group. In the intention-to-treat analysis, intubation occurred in 35 (17%) patients assigned to prolonged awake prone positioning and in 56 (27%) patients assigned to standard care (relative risk 0.62 [95% confidence interval (CI) 0.42-0.9]). The hazard ratio (HR) for intubation was 0.56 (0.37-0.86), and for mortality was 0.63 (0.42-0.96) for prolonged awake prone positioning versus standard care, within 28 days. The incidence of pre-specified adverse events was low and similar in both groups.

CONCLUSION: Prolonged awake prone positioning of patients with COVID-19-related AHRF reduces the intubation rate without significant harm. These results support prolonged awake prone positioning of patients with COVID-19-related AHRF.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Liu L, Sun Q, Zhao H, et al. Prolonged vs shorter awake prone positioning for COVID-19 patients with acute respiratory failure: a multicenter, randomised controlled trial. Intensive Care Med. 2024. PMID: 39088076. doi:10.1007/s00134-024-07545-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。